Bellicum Pharmaceuticals (BLCM) IPO Opens Up 29%

Today's IPO for Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) opened for trading at $24.56 after pricing 7,350,000 shares of its common stock, an increase of 1,100,000 shares from the number of shares originally offered, at a public offering price of $19.00 per share.

In addition, Bellicum has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the offering price.

Jefferies LLC, Citigroup Global Markets Inc. and Piper Jaffray & Co. are acting as joint book running managers for the offering and Trout Capital LLC is acting as co-manager for the offering.

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• MapLight Therapeutics raises $150M in private placement
• OpenAI revenue chief quits after less than a year